Guidelines

FDA issues draft guidance for biosimilar meetings

Home/Guidelines | Posted 05/04/2013

FDA announced on 1 April 2013 that it had issued draft guidance for biosimilar meetings outlining standardized procedures for requesting, preparing, scheduling, conducting and documenting such formal meetings with FDA.

Guideline update on prevention of febrile neutropenia with G-CSF

Home/Guidelines | Posted 29/03/2013

Patients undergoing chemotherapy for cancer are at risk of developing the sometimes fatal condition of febrile neutropenia (FN), involving infection, fever and sepsis due to a loss of neutrophils. Prophylaxis with recombinant granulocyte colony-stimulating factor (G-CSF) has been shown to reduce hospital admissions, antibiotic use and the need for chemotherapy dose reduction. Several forms of recombinant G-CSF are available, including filgrastim and its biosimilars, or the pegylated version of filgrastim. All three are considered to be equivalent in terms of clinical efficacy and safety.

EMA releases guidelines on biosimilar interferon beta and r-FSH

Home/Guidelines | Posted 15/03/2013

In March 2013, EMA released two guidelines on how pharmaceutical companies should test biosimilar medicines containing interferon beta and recombinant follicle stimulation hormone (r-FSH).

Egypt issues draft guidelines for biosimilars

Home/Guidelines | Posted 01/03/2013

The Egyptian Drug Authority (EDA) announced on 20 January 2013 that a draft guideline for the registration of biosimilars in Egypt had been released by the Central Administration for Pharmaceutical Affairs (CAPA) in coordination with the National Organization for Research & Control of Biologics (NORCB).

Draft revision of biosimilar low molecular weight heparin guideline

Home/Guidelines | Posted 08/02/2013

EMA announced on 31 January 2013 that it had released a draft guideline to revise the agency’s current guideline on biosimilars containing low molecular weight heparins (LMWHs). The draft guideline will be released for a six-month public consultation period.

China’s SFDA to fast-track high-priority generics

Home/Guidelines | Posted 01/02/2013

China’s State Food and Drug Administration (SFDA) has set out a number of proposed changes to the drug registration process, providing encouragement for domestic innovation and allowing the fast-track review of generic drugs which answer an unmet clinical need.

EMA publishes draft guideline for biosimilar human insulin

Home/Guidelines | Posted 11/01/2013

EMA announced on 14 December 2012 that it had published a draft guideline revising its current guideline on the non-clinical and clinical development of biosimilar human insulin and insulin analogues. The draft guideline will be released for a six-month public consultation period.

CESP makes submissions totally electronic

Home/Guidelines | Posted 14/12/2012

The Dutch Medicines Evaluation Board (CBG-MEB) announced on 1 November 2012 that starting from 12 November 2012, it will be possible to submit applications for marketing authorizations and deviations in the national, MRP (mutual recognition procedure) or DCP (decentralized procedure) procedures through the improved Common European Submission Platform (CESP).

China to release biosimilars guidelines

Home/Guidelines | Posted 23/11/2012

China, one of the largest pharmaceutical markets in the world, is ready to issue biosimilars guidelines.

Health Canada publishes draft GMP guideline for APIs

Home/Guidelines | Posted 09/11/2012

Health Canada announced on 22 October 2012 the publication of a draft guideline on good manufacturing practices (GMP) for active pharmaceutical ingredients (APIs).